Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Med Sci ; 15(6): 574-579, 2018.
Article in English | MEDLINE | ID: mdl-29725247

ABSTRACT

Chemotherapy is one of effective methods for the treatment of tumor. Patients often develop drug resistance after chemotherapic cycles. Salmonella has potential as antitumor agent. Salmonella used in tandem with chemotherapy had additive effects, providing a rationale for using tumor-targeting Salmonella in combination with conventional chemotherapy. To improve the efficacy and safety of Salmonella, a further understanding of Salmonella interactions with the tumor microenvironment is required. The presence of plasma membrane multidrug resistance protein P-glycoprotein (P-gp) is highly relevant for the success of chemotherapy. Following Salmonella infection, dose-dependent downregulation of P-gp expressions were examined. Salmonella significantly decreased the efflux capabilities of P-gp, as based on the influx of Rhodamine 123 assay. In addition, Salmonella significant reduced the protein express the expression levels of phosph-protein kinase B (P-AKT), phosph-mammalian targets of rapamycin (P-mTOR), and phosph-p70 ribosomal s6 kinase (P-p70s6K) in tumor cells. The Salmonella-induced downregulation of P-gp was rescued by transfection of cells with active P-AKT. Our results demonstrate that Salmonella in tumor sites leads to decrease the expression of P-gp and enhances the combination of Salmonella and 5-Fluorouracil therapeutic effects.


Subject(s)
Fluorouracil/administration & dosage , Melanoma, Experimental/drug therapy , Melanoma, Experimental/microbiology , Salmonella Infections/genetics , Salmonella/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Animals , Cell Membrane/drug effects , Cell Membrane/genetics , Combined Modality Therapy , Drug Resistance, Multiple/genetics , Gene Expression Regulation, Neoplastic/genetics , Humans , Melanoma, Experimental/pathology , Mice , Proto-Oncogene Proteins c-akt/genetics , Ribosomal Protein S6 Kinases, 70-kDa/genetics , Salmonella/pathogenicity , Salmonella Infections/microbiology , Salmonella Infections/pathology , TOR Serine-Threonine Kinases/genetics , Tumor Microenvironment/drug effects
2.
Oncotarget ; 7(25): 37513-37523, 2016 Jun 21.
Article in English | MEDLINE | ID: mdl-27175584

ABSTRACT

Salmonella is a Gram-negative, facultative anaerobe that is a common cause of host intestinal infections. Salmonella grows under aerobic and anaerobic conditions, and it has been proven capable of inhibiting tumor growth. However, the molecular mechanism by which Salmonella inhibits tumor growth is still unclear. Angiogenesis plays an important role in the development and progression of tumors. We investigated the antitumor effect of Salmonella in a syngeneic murine tumor model. Hypoxia-inducible factor-1 (HIF-1)α plays a significant role in tumor angiogenesis. We examined the molecular mechanism by which Salmonella regulated vascular endothelial growth factor (VEGF), which is an important angiogenic factor. The expression of VEGF in tumor cells was decreased by treatment with Salmonella. The conditioned medium from Salmonella-treated cells inhibited the proliferation of endothelial cells. Salmonella inhibited the expression of HIF-1α as well as downregulated its upstream signal mediator protein kinase B (AKT). Salmonella significantly inhibited tumor growth in vivo, and immunohistochemical studies of the tumors revealed decreased intratumoral microvessel density. These results suggest that Salmonella therapy, which exerts anti-angiogenic activities, represents a promising strategy for the treatment of tumors.


Subject(s)
Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Mammary Neoplasms, Experimental/blood supply , Mammary Neoplasms, Experimental/microbiology , Melanoma, Experimental/blood supply , Melanoma, Experimental/microbiology , Salmonella enterica/physiology , Vascular Endothelial Growth Factor A/metabolism , Animals , Culture Media, Conditioned , Down-Regulation , Endothelial Cells/cytology , Endothelial Cells/metabolism , Endothelial Cells/microbiology , Female , Humans , Mammary Neoplasms, Experimental/metabolism , Melanoma, Experimental/metabolism , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/microbiology , Neovascularization, Pathologic/pathology , Salmonella enterica/metabolism , Signal Transduction , Transfection
3.
Environ Toxicol ; 31(1): 77-84, 2016 Jan.
Article in English | MEDLINE | ID: mdl-25044443

ABSTRACT

Hinokitiol is found in the heartwood of cupressaceous plants and possesses several biological activities. Hinokitiol may play an important role in anti-inflammation and antioxidant processes, making it potentially useful in therapies for inflammatory-mediated disease. Previously, the suppression of tumor growth by hinokitiol has been shown to occur through apoptosis. Programmed cell death can also occur through autophagy, but the mechanism of hinokitiol-induced autophagy in tumor cells is poorly defined. We used an autophagy inhibitor (3-methyladenine) to demonstrate that hinokitiol can induce cell death via an autophagic pathway. Further, we suggest that hinokitiol induces autophagy in a dose-dependent manner. Markers of autophagy were increased after tumor cells were treated with hinokitiol. In addition, immunoblotting revealed that the levels of phosphoprotein kinase B (P-AKT), phosphomammalian target of rapamycin (P-mTOR), and phospho-p70 ribosomal s6 kinase (P-p70S6K) in tumor cells were decreased after hinokitiol treatment. In conclusion, our results indicate that hinokitiol induces the autophagic signaling pathway via downregulation of the AKT/mTOR pathway. Therefore, our findings show that hinokitiol may control tumor growth by inducing autophagic signaling.


Subject(s)
Autophagy/drug effects , Monoterpenes/toxicity , Tropolone/analogs & derivatives , Animals , Apoptosis/drug effects , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Line, Tumor , Cell Survival/drug effects , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Female , Mice , Monoterpenes/therapeutic use , Proto-Oncogene Proteins c-akt/metabolism , Ribosomal Protein S6 Kinases, 70-kDa/metabolism , Signal Transduction/drug effects , TOR Serine-Threonine Kinases/metabolism , Tropolone/therapeutic use , Tropolone/toxicity
4.
Environ Toxicol ; 30(8): 877-86, 2015 Jul 08.
Article in English | MEDLINE | ID: mdl-24449132

ABSTRACT

Although current studies indicate that resveratrol exhibits potential antitumor activities, the precise mechanisms of its beneficial effects combined with chemotherapy are not fully understood. This work is warranted to elucidate the underlying mechanism of antitumor effects by the combination therapy of resveratrol and cisplatin. The presence of functional gap junctions is highly relevant for the success of chemotherapy. Gap junctions mediate cell communication by allowing the passage of molecules from one cell to another. Connexin (Cx) 43 is ubiquitous and reduced in a variety of tumor cells. Cx43 may influence the response of tumor cells to treatments by facilitating the passage of antitumor drugs or death signals between neighboring tumor cells. Following resveratrol treatment, dose-dependent upregulation of Cx43 expressions was observed. In addition, gap junction intercellular communication was increased. To study the mechanism underlying these resveratrol-induced Cx43 expressions, we found that resveratrol induced a significant increase in mitogen-activated protein kinases (MAPK) signaling pathways. The MAPK inhibitors significantly reduced the expression of Cx43 protein after resveratrol treatment. Specific knockdown of Cx43 resulted in a reduction of cell death after resveratrol and cisplatin treatment. Our results suggest that treatment of resveratrol in tumor leads to increase Cx43 gap junction communication and enhances the combination of resveratrol and cisplatin therapeutic effects. © 2014 Wiley Periodicals, Inc. Environ Toxicol 30: 877-886, 2015.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Connexin 43/biosynthesis , Melanoma, Experimental/drug therapy , Melanoma, Experimental/metabolism , Stilbenes/pharmacology , Animals , Antineoplastic Agents/pharmacology , Cell Death/drug effects , Cell Line, Tumor , Cisplatin/pharmacology , Connexin 43/genetics , Dose-Response Relationship, Drug , Gap Junctions/drug effects , Male , Mice , Mice, Inbred C57BL , Mitogen-Activated Protein Kinases/metabolism , Resveratrol , Signal Transduction/drug effects , Up-Regulation/drug effects
5.
Int J Cancer ; 133(8): 1926-35, 2013 Oct 15.
Article in English | MEDLINE | ID: mdl-23558669

ABSTRACT

The use of preferentially replicating bacteria as oncolytic agents is one of the innovative approaches for the treatment of cancer. The capability of Salmonella to disperse within tumors and hence to delay tumor growth was augmented when combined with chemotherapy. This work is warranted to elucidate the underlying mechanism of antitumor effects by the combination therapy of Salmonella and cisplatin. The presence of functional gap junctions is highly relevant for the success of chemotherapy. Following Salmonella treatment, dose- and time-dependent upregulation of connexin 43 (Cx43) expressions were observed. Moreover, Salmonella significantly enhanced gap intercellular communication (GJIC), as revealed by the fluorescent dye scrape loading assay. To study the pathway underlying these Salmonella-induced effects, we found that Salmonella induced a significant increase in mitogen-activated protein kinases (MAPK) signaling pathways. The Salmonella-induced upregulation of Cx43 was prevented by treatment of cells with the phosphorylated p38 inhibitor, but not phosphorylated extracellular signal-regulated kinase (pERK) inhibitor or phosphorylated c-jun N terminal kinase (pJNK) inhibitor. Specific knockdown of Cx43 had an inhibitory effect on GJIC and resulted in a reduction of cell death after Salmonella and cisplatin treatment. Our results suggest that accumulation of Salmonella in tumor sites leads to increase Cx43 gap junction communication and enhances the combination of Salmonella and cisplatin therapeutic effects.


Subject(s)
Antineoplastic Agents/therapeutic use , Cisplatin/therapeutic use , Connexin 43/metabolism , Neoplasms/drug therapy , Salmonella/metabolism , Animals , Apoptosis/drug effects , Biological Therapy , Cell Communication/drug effects , Cell Line, Tumor , Connexin 43/genetics , Enzyme Inhibitors/pharmacology , Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors , Flavonoids/pharmacology , Gap Junctions/drug effects , Gap Junctions/metabolism , Gap Junctions/microbiology , Imidazoles/pharmacology , JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors , MAP Kinase Signaling System , Mice , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Neoplasms/microbiology , Protein Kinase Inhibitors/pharmacology , Pyridines/pharmacology , RNA Interference , RNA, Small Interfering , Up-Regulation , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
6.
Exp Biol Med (Maywood) ; 237(10): 1189-96, 2012 Oct.
Article in English | MEDLINE | ID: mdl-23045719

ABSTRACT

Systemic administration of Salmonella to tumor-bearing mice leads to the preferential accumulation within tumor sites and retardation of tumor growth. The cancer stem-like cell (CSC) hypothesis suggests that CSCs are the root of cancer and induce metastasis and recurrence. The objective of this study was to examine if Salmonella could inhibit the growth of CSCs derived from mouse breast cancer. Systemically injected Salmonella preferentially accumulated within tumors for at least three weeks and the bacteria accumulated preferentially not only in subcutaneous but also in orthotopic tumors over livers and spleens at ratios ranging from 1000:1 to 10,000:1. Salmonella were capable of delaying tumor growth and enhancing survival in both subcutaneous and orthotopic tumor models. More strikingly, Salmonella acted to retard tumor growth and extensively prolong the survival time of the mice bearing CSC-induced tumors. Our results also found that Salmonella predominantly, although not exclusively, resided in the CSC regions of the tumor. These data suggest that Salmonella can inhibit the growth of breast cancer by targeting the CSC niche. In conclusion, Salmonella can be used for the management of breast cancer.


Subject(s)
Breast Neoplasms/pathology , Neoplastic Stem Cells/microbiology , Neoplastic Stem Cells/pathology , Salmonella , Animals , Cell Line, Tumor , Female , Mice , Mice, Inbred BALB C , Neoplasm Transplantation , Stem Cell Niche , Transplantation, Heterologous
7.
Innate Immun ; 18(5): 685-93, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22344225

ABSTRACT

Epithelial to mesenchymal transition (EMT) has been linked to metastasis. Resveratrol exhibits potential antitumor activities; however, the inhibitory effects of resveratrol on the EMT of melanoma have not been demonstrated. Here, a new role for LPS in promoting EMT is described. LPS-induced EMT was identified by examining the markers of EMT. To assess the activation of NF-κB signal transduction pathway, we performed a reporter assay by using tumor cells transfected with the luciferase gene under the control of NF-κB response elements. The antitumor effects of resveratrol were evaluated in an experimental mouse metastasis tumor model. LPS increased N-cadherin and Snail expression and decreased zonula occludens-1 expression in a dose- and time-dependent manner. Meanwhile, LPS stimulated cell migration through activation of TLR4/NF-κB signal pathway. LPS-induced EMT is critical for inflammation-initiated metastasis. Nuclear translocation and transcriptional activity of p65 NF-κB, an important inducer of EMT, were inhibited by resveratrol. Resveratrol inhibited LPS-induced tumor migration and markers of EMT, significantly prolonged animal survival and reduced the tumor size. Thus, resveratrol plays an important role in the inhibition of LPS-induced EMT in mouse melanoma through the down-regulation of NF-κB activity. The data provide an insight into the mechanisms on the function of resveratrol during the processes of EMT.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Epithelial-Mesenchymal Transition/drug effects , Melanoma/drug therapy , Skin Neoplasms/drug therapy , Stilbenes/administration & dosage , Animals , Biomarkers, Tumor/metabolism , Cadherins/genetics , Cadherins/metabolism , Disease Models, Animal , Gene Expression Regulation, Neoplastic , Humans , Lipopolysaccharides/metabolism , Male , Melanoma/secondary , Mice , Mice, Inbred C3H , NF-kappa B/metabolism , Resveratrol , Signal Transduction , Skin Neoplasms/pathology , Snail Family Transcription Factors , Transcription Factors/genetics , Transcription Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...